CTLA4 and neoplasm: Immunotherapies are, by default, founded on an understanding of the TIME, often with respect to effector T lymphocyte function; the clinical benefits of ICI rely on disabling T cell suppression through targeting molecules such as PD-1/PD-L1 or cytotoxic T-lymphocyte-associated protein 4 (CTLA-4)—on the condition that the tumour is, in fact, taking advantage of these regulatory mechanisms to induce immune tolerance [157].